The physics and physiology of lung surfactants

Current Opinion in Colloid and Interface Science

Volumn 6, Issue 5-6, 2001, Pages 506-513

  Zasadzinski, J A ^a   Ding, J ^a   Warriner, H E ^a   Bringezu, F ^a   Waring, Alan J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Lung surfactants; Monolayers; Palmitic acid; Phase behavior; Phosphatidylcholines

Indexed keywords

LUNG SURFACTANT; PHOSPHATIDYLCHOLINE;

BEHAVIORISM; CELL SPREADING; EXPERIMENTAL MODEL; FUNCTIONAL ASSESSMENT; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LUNG ALVEOLUS; LUNG ALVEOLUS SURFACE TENSION; MOLECULAR DYNAMICS; MONOLAYER CULTURE; MORPHOLOGY; PHASE TRANSITION; PHYSICAL PHASE; PHYSICS; PHYSIOLOGY; REVIEW; VISCOSITY;

EID: 0035202767     PISSN: 13590294     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-0294(01)00124-8     Document Type: Review

References (45)

1. Surface properties in relation to atelectasis and hyaline membrane disease
2. Surface phenomena in relation to pulmonary function
3. Pulmonary surfactant: Functions and molecular composition
4. Lung surfactants: Basic science and clinical applications
5. Commercial versus native surfactants
6. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks gestation: A randomised trial
7. Which surfactant for treatment of respiratory distress syndrome?
8. The effects of synthetic and natural surfactant on fluid balance in acute respiratory distress syndrome
9. Coexistence of buckled and flat monolayers
10. Effects of lung surfactant proteins SP-B and SP-C and palmitic acid on monolayer stability
11. Interaction of lung surfactant proteins with anionic phospholipids
12. A concentration-dependent mechanism by which serum albumin inactivates replacement surfactants
13. Changes in model lung surfactant monolayers induced by palmitic acid
14. Synchrotron X-ray study of lung surfactant specific protein SP-B in lipid monolayers
15. 13C-enhanced Fourier-transform infrared spectroscopy
16. Thirty years of clinical trials in acute respiratory distress syndrome
17. Sensitivity of synthetic surfactants to albumin inhibition in preterm rabbits
18. Bronchoalveolar lavage fluid characteristics of early intermediate and late phases of ARDS. Alterations in leukocytes, proteins, PAF and surfactant components
19. Multiple mechanisms of lung surfactant inhibition
20. Large porous particles for pulmonary drug delivery
21. Formulation and physical characterization of large porous particles for inhalation
22. Novel, lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract
23. Non-ionic polymers reverse inactivation of surfactant by meconium and other substances
24. Principles of surfactant replacement
25. The role of lipids in pulmonary surfactant
26. Surfactant protein A (SP-A): The alveolus and beyond
27. Structure and properties of surfactant protein B
28. Surfactant replacement in patients with ARDS: Result of clinical trials
29. Synthetic surfactant protein analogues
30. Phase transitions in films of lung surfactant at the air-water interface
31. Influence of phospholipid composition on the properties of reconstituted surfactants
32. Structure and phase transitions in Langmuir monolayers
33. Neutral lipids induce critical behavior in interfacial monolayers of pulmonary surfactant
34. Phase separation in monolayers of pulmonary surfactant phospholipids at the air-water interface: Composition and structure
35. Persistence of phase coexistence in disaturated phosphatidylcholine monolayers at high surface pressures
36. Influence of palmitic acid and hexadecanol on the phase transition temperature and crystal structure of DPPC monolayers at the air-water interface
37. Unstable topography of biphasic surfactant monolayers
38. The structure of a model pulmonary surfactant as revealed by scanning force microscopy
39. Formation of three-dimensional protein-lipid aggregates in monolayer films induced by surfactant protein B
40. Development of synthetic lung surfactants
41. The role of palmitic acid in pulmonary surfactant: Enhancement of surface activity and prevention of inhibition by blood proteins
42. Initial clinical trials of Exosurf, a protein-free synthetic surfactant for the prophylaxis and early treatment of hyaline membrane disease
43. Miscibility critical pressures in monolayers of ternary mixtures
44. Stripe phases in lipid monolayers near a miscibility critical point
45. Red blood cells form immiscible liquids